|
|
|
|
Be part of the latest molecular imaging megatrend
|
|
|
|
The frontiers of bioimaging are currently being pushed toward the integration and correlation of several modalities to tackle biomedical research questions comprehensively, across multiple scales and dimensions. Correlated Multimodal Imaging (CMI) gathers information from exactly the same specimen under identical conditions and at virtually the same time, using complementary modalities that in combination create a composite and complementary view of the sample, including insights into structure, function, dynamics, and molecular composition.
|
|
|
Unmatched image clarity from UHR-SPECT
|
|
|
By dramatically improving temporal and spatial resolution of cardiac SPECT, MILabs’ 4D U-SPECT offers several advantages over microCT and microMRI: (1) the capability, with a single acquisition, to quantify radiotracer uptake in the myocardium and to identify global or regional ischemia, (2) detection of molecular probes with a 103-106 greater sensitivity than MRI techniques, and (3) extract both ventricular and atrial wall kinetics and correlate these to local defects in perfusion innervation, and tissue viability.
“Because of its high sensitivity and resolution, MILabs U-SPECT should be considered as an excellent modality for studying mouse models of cardiac disease”. Read more from Duke University.
|
|
|
Only UHD-PET enables 82Rb imaging and one-to-one SPECT/PET translation
|
|
|
By eliminating the positron range effect of 82Rb, MILabs ultra-high-definition PET (UHD-PET) is the first animal PET system that can perform myocardial perfusion imaging and blood flow quantitation with PET at sub-mm resolutions. Additionally, simultaneous dual-isotope 18F-FDG/82Rb PET enables to corelate perfusion, tissue viability and metabolism. Read more from TU Delft.
But there is more. Holistic multimodality imaging with the VECTor7 platform enables simultaneous imaging of PET and SPECT isotopes. Now you can make one-to-one comparisons between SPECT and PET cardiac tracers, automatically correlated in space and time. Click here for more information.
|
|
|
Calcium scoring and CE-CT angiography
|
|
|
Besides dual tracer radioisotope imaging, one of the features of the MILabs VECTor system our users value very much is the decoupling of the CT gantry from the actual SPECT acquisition. Such a higher-end, autonomous CT and rotation-free SPECT system is equivalent to diagnostic CT scanners and thus capable of diagnostic CT protocols like calcium scoring and angiography (CTA).
“This allows for the diagnostic evaluation of an animal using both nuclear and CT in a single imaging session. The acquisition of a CTA on the same camera as PET or SPECT facilitates accurate co-registration of complementary datasets”. Read more from Yale University.
|
|
|
Gated-CT to study COVID-19 in heart and lung vasculature
|
|
|
Dual-gated cardiac and respiratory gated acquisitions enable imaging of the microscopic dimensions of coronary vessels. The high temporal and spatial X-ray CT resolution of the system enables to study SARS-CoV-2 toxicity in cardiopulmonary vessels of mice.
“Designed as a scalable all-in-one platform, each individual modality of VECTor4CT – whether X-ray CT, PET or SPECT – offers performance beyond the capabilities of any other preclinical imaging system in terms of image quality and in-vivo imaging functionality.” Click here for more information from Queens University.
|
|
|
Image-guided therapy after a heart attack
|
|
|
|
Yale researchers use U-SPECT/CT for cardiac ischemia-reperfusion imaging in mice. As illustrated, the reduced perfusion area can be quantified. At 3-days and 6-weeks post-ischemia, the same area shows an increase in the radiotracer uptake of the matrix metalloproteinase agent, 99mTc RP805. This tracer is used as an index of cardiac remodeling.
Intramyocardial delivery of hydrogel post-MI resulted in increased integrin activation in MI region and decreased LV remodeling. Dynamic UHR-SPECT/CT imaging is a feasible approach for guiding delivery and monitoring the effects of a therapeutic hydrogel in a MI mouse model.
|
|
|
Correlative optical/CT extends applications beyond possible
|
|
|
Once you see the tomographic results from CT-guided fluorescence (FLT) or bioluminescence (BLT) imaging, you want to retire any standard in-vivo optical imaging equipment. As comparatively illustrated on the left, the implementation of FLT/ CT reveals fluorescent probe activity in deep tissue not visible with standard optical tomographic techniques. Now one can visualize optical cardiac imaging applications such as Osteosense vascular calcification, stem cell targeting, and ICG angiography. Click here for more information from RWTH Aachen University.
As illustrated by the unique capabilities of FLT/CT, MILabs’ CLM imaging approach, which simultaneously gathers multi-modal information from the same specimen, is bound to expand applications beyond what has been possible.
|
|
|
Contrast-enhanced CT for measuring hemodynamics
|
|
|
In a recent front cover article from researchers at Yale University, researchers demonstrated that the high-resolution diagnostic capabilities of U-SPECT/CT can be used to image the spatial and pressure distribution artery-to-vein fistulae in rodents. Click here for more information.
|
|
|
Be part of an “Innovation that is conquering the world”
|
|
|
Innovation Origins – a publication from the Federation of Dutch Universities – puts the spotlight on MILabs, one of the most successful spin-offs of these universities. The publication describes the company’s origin, including the founding by F. Beekman, physicist, scientist, and innovator.
Over the years, MlLabs was supported by two Dutch universities from the moment it started with a groundbreaking SPECT technology. Today, the company is a provider of state-of-the-art “all-in-one scanners for biomedical research”. Its unique correlative multimodal systems use a fully integrated platform of X-ray CT, PET, SPECT and Optical tomography systems. Now under the wings of Rigaku – a large innovative Japanese company – MILabs is entering a new development stage to grow its market share in the global biomedical research world. Read more
|
|
|
MILabs seeks talented individuals to further scale-up its organization.
|
|
|
|
|
|
|
